Group 1: International Relations and Trade - China will implement a visa-free policy for Russian citizens holding ordinary passports from September 15, 2025, to September 14, 2026, allowing stays of up to 30 days for business, tourism, family visits, and transit [1] - The Shanghai Cooperation Organization (SCO) leaders have issued a statement supporting the multilateral trading system, emphasizing the importance of development and the integration of least developed countries into the trade system [1] - China aims to strengthen communication and cooperation with SCO member states to promote genuine multilateralism and push for reforms in the World Trade Organization (WTO) [1] Group 2: Social Security and Tax Policies - The Ministry of Finance and the State Taxation Administration have announced tax policies regarding the transfer of state-owned equity and cash income to bolster the social security fund, including exemptions from VAT and corporate income tax for certain transactions [2] - The policy aims to facilitate the management of state-owned assets and enhance the financial sustainability of the social security fund [2] Group 3: Software Industry Performance - In the first seven months of 2025, China's software industry generated revenue of 83,246 billion yuan, reflecting a year-on-year growth of 12.3% [3] - The total profit of the software industry reached 10,890 billion yuan, with software product revenue accounting for 21.6% of the total industry revenue [3] - Information technology services contributed 57,246 billion yuan, representing 68.8% of the overall revenue, indicating a strong performance in this sector [3] Group 4: Biopharmaceutical Industry Development - The State-owned Assets Supervision and Administration Commission (SASAC) is focusing on accelerating the development of the biopharmaceutical industry, aiming to create a national team in this field [4] - The initiative emphasizes innovation-driven development and collaboration with the Chinese Academy of Sciences to enhance the quality and competitiveness of China's biopharmaceutical sector [4]

盘面上，大型科技股飘绿，阿里巴巴跌1.75%，腾讯跌0.74%。机器人概念股午后拉升，微创机器人大 涨12%，力劲科技涨近11%；上市银行上半年业绩明显回暖，内银股逆市活跃；车企披露上月交付数 据，汽车股走势分化，比亚迪股份涨超2%，小鹏汽车跌近3%。另一边，芯片、算力方向显著调整；苹 果概念、加密货币概念、内房股等普遍承压。 智通财经APP获悉，港股未能延续昨日涨势，三大指数早盘小幅冲高后回落。其中，恒科指表现最弱， 盘中一度跌近2%。截止收盘，恒生指数跌0.47%或120.87点，报25496.55点，全日成交额为3281.19亿港 元；恒生国企指数跌0.15%，报9108.12点；恒生科技指数跌1.22%，报5728.46点。 国泰海通证券认为，中国转型进展加快、无风险收益下沉、资本市场改革推动下中国股市不会止步，还 会走出新高。宽松预期升温与经济能见度提高，行情扩散中盘崛起；看好港股反弹。交银国际则表示， 宏观环境趋稳出流动性宽松，港股有望延续向好态势。 蓝筹股表现 小米集团-W(01810)表现亮眼。截至收盘，涨3.43%，报55.85港元，成交额143.16亿港元，贡献恒指 52.91点。9月1日 ...

Core Viewpoint - *ST Huicheng has selected Zhi'en Biotechnology as the restructuring investor during its pre-restructuring phase, but no formal agreement has been signed yet, leaving future collaboration uncertain [1][2] Group 1: Company Developments - *ST Huicheng has experienced a stock price increase of 15.83% over three consecutive trading days, followed by a decline of 4.95% on the latest trading day, closing at 4.80 yuan [1] - The company has initiated the recruitment of restructuring investors since August 9, with three potential investors meeting the requirements and submitting their materials [1] - Zhi'en Biotechnology was selected as the restructuring investor based on a comprehensive evaluation of submitted restructuring investment proposals [1][2] Group 2: Zhi'en Biotechnology Overview - Zhi'en Biotechnology, established in April 2001, focuses on building a drug lifecycle management service system and holds various qualifications, including being a national high-tech enterprise [2] - The company has over 50 products, including key medications such as orlistat capsules for weight loss and donepezil hydrochloride tablets for Alzheimer's disease [2][3] - Zhi'en Biotechnology is the largest global supplier of orlistat, having achieved full synthetic industrial production of the active pharmaceutical ingredient [3] Group 3: Previous Collaborations - Prior to the restructuring investment selection, *ST Huicheng and Zhi'en Biotechnology had collaborated, with *ST Huicheng acquiring a 51% stake in Chongqing Rui'en Pharmaceutical for 47 million yuan [4] - The biopharmaceutical business, including Rui'en Pharmaceutical, has become a significant revenue contributor for *ST Huicheng, accounting for 57.41% of its revenue in the first half of the year [4] - Rui'en Pharmaceutical reported a revenue of 122 million yuan and a net profit of 23.44 million yuan in the first half of the year [4]

东方财富证券指出，2025Q2腾讯、阿里两大龙头财报表现亮眼，AI相关业务已体现明显业绩贡献，阿 里AI芯片业务的布局进一步打开远期想象空间。此外，港股流动性近期迎来边际改善，鲍威尔表态转 鸽，港汇脱离弱方兑换保证，Hibor快速上行后维稳，前期港股资产价格的估值压制正逐步缓解。科技 成长风格中，港股科技板块后续仍具备潜在催化。 注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相 匹配的产品。基金有风险，投资需谨慎。 没有股票账户的投资者可关注国泰中证港股通科技ETF发起联接C（015740），国泰中证港股通科技 ETF发起联接A（015739）。 港股科技ETF（代码：513020）跟踪的是港股通科技指数（代码：931573），该指数由中证指数有限公 司编制，从港股通范围内上市的科技行业公司中精选不超过50家优质企业作为成分股。重点覆盖"互联 网+生物医药+新能源车+芯片"等多个细分领域 ...

Core Viewpoint - Fosun International emphasizes a clear strategic focus on core businesses, deepening global layout, and increasing innovation investment to establish a solid foundation for future development [1] Group 1: Strategic Developments - The management highlighted the strategy of "progress and retreat," optimizing asset structure, and has completed the sale of 99.743% of its stake in the German private bank HAL by June 30, 2025 [1] - Citigroup raised the target price for Fosun from HKD 5.86 to HKD 6.50, citing a significant discount of 72% to NAV, indicating potential for valuation recovery [1][2] - The company has seen a reduction of over 30 basis points in financing costs compared to the end of 2024, supported by the expansion of overseas dollar bonds and domestic debt issuance [1][2] Group 2: Financial Performance - Fosun's core industries, such as innovative pharmaceuticals, have achieved multiple breakthroughs, with the innovative drug H achieving global sales revenue of RMB 5.977 billion [2] - The overseas revenue proportion reached 53%, an increase of 6.6 percentage points year-on-year, reflecting the effectiveness of global business layout [2] - The insurance segment reported revenue of RMB 20.89 billion in the first half of the year, with significant growth in the Portuguese insurance market and a 25.1% increase in Dingrui Reinsurance's gross premium income [2] Group 3: Technological Innovations - Fosun continues to innovate in the fintech sector, launching the FinRWA Platform (FRP) and actively promoting asset tokenization projects [3] - The company has upgraded its licenses for securities and asset management, with steady progress in virtual assets and RWA platform development [3] Group 4: Market Sentiment - Domestic and international brokerages have expressed optimism about Fosun's future prospects and long-term value, with a consensus on the company's strategic direction and asset optimization efforts [1][3]

Core Viewpoint - The Hang Seng Index experienced a significant increase, closing at 25,617.42 points with a rise of 2.15%, driven by strong performances from major constituents like Alibaba, WuXi Biologics, and Zijin Mining, indicating a positive outlook for Hong Kong stocks amid easing external conditions [1] Market Performance - The Hang Seng Index opened high on September 1 and maintained strong performance throughout the day, with notable gains in technology, pharmaceuticals, and materials sectors [1] - Alibaba's mid-term earnings report exceeded market expectations, with cloud intelligence service revenue growing by 26% year-on-year, reinforcing the growth narrative driven by AI [1] Valuation and Comparison - The Hang Seng Technology Index currently has a price-to-earnings ratio of 21.23, which is below the historical 20% percentile, suggesting a more reasonable valuation compared to A-shares [1] - Historically, during periods of RMB appreciation, the median annualized return of the Hang Seng Index reached 36.5%, outperforming the 29.8% of the CSI 300 [1] Sector Strength - The composition of Hong Kong stocks, particularly in technology and pharmaceuticals, is seen as advantageous compared to A-shares, with a higher concentration of growth stocks [1] - The improving sentiment in AI internet and innovative pharmaceuticals sectors is expected to support further upward movement in Hong Kong stocks, with potential for valuation increases [1] Investment Recommendation - Investors are encouraged to maintain focus on Hong Kong technology ETFs, particularly those encompassing internet, semiconductors, innovative pharmaceuticals, and new energy vehicles [2]

丹纳赫集团是世界范围内近40年并购最为成功的产业公司，它的出手次数、规模和业绩回报甚至可以比肩以企业并购为核心业务的私募巨擘黑石和 KKR。在丹纳 赫集团40多年的发展过程中，总计完成了近 400 次并购，花费约900亿美元，配合DBS赋能的超一流经营能力，创造出了市值约 2000 亿美元的丹纳赫集团以及一 众经由丹纳赫集团分拆、出售而成的其他上市企业，如福迪威、盈纬达、Vontier、Veralto 等。如果将其分拆和出售公司算在内，丹纳赫集团为股东创造了约 2500 亿美元的价值。 凭借着战略并购和 DBS 运营的双轮驱动，丹纳赫集团的股价在过去 40 年达到了年均 22% 的回报率，不仅远超标普 500 指数年均 12% 的表现，更是压过巴菲特执 掌的伯克希尔 - 哈撒韦同期 16% 的股东回报率。这个股东回报率与同期的苹果公司几乎相当。 那么，这样一家巨无霸企业究竟是如何通过并购建成的？丹纳赫集团在不同时期的并购风格和价值创造模式分别是什么？并购背后的流程和团队是如何演化的？ 由丹纳赫中国区前高管杨益、陈朝巍合著的《丹纳赫模式》一书，首次系统拆解丹纳赫集团并购整合的核心能力，揭示"并购之王"究竟是如何 ...

点击蓝字，关注我们 | | 星期一 | 星期二 | 星期三 | 星期四 | 星期五 | | --- | --- | --- | --- | --- | --- | | | 09/01 | 09/02 | 09/03 | 09/04 | 09/05 | | 港股业绩发布 | | 00943 | | 00016 | 03988 | | (北京时间) | | 中证国际 | | 新鸿基地产 | 中国银行 | | | | NIO | CRM | AVGO | ABM | | | | 蔚来 | 赛富时 | 博通 | 얻을工亦 | | | | [盘前] | [審ළ] HFP | [盘后] CRPT | [盘前] | | | | | 慧与科技 [盎닫] | 卡帕特 [盘层] LULU | | | | | | DLTR | Lululemon | | | 美股业绩发布 | | | 美元树公司 | | | | | | | 「盘前」 | Athletica | | | (美东时间) | | | | [盘后] | | | | | | M | | | | | | | 梅西自货 | | | | | | | Al | | | | | | ...

2025年9月2日早间A股开盘后三大指数震荡走弱，从盘面上看，两部门印发《工业母机高质量标准体系 建设方案》，概念股集体走强；AI硬件端有所降温。 融资融券方面，昨日沪深两市的融资融券余额为22896.58亿元，超过了2015年的峰值2.27万亿元，创下 历史新高！其中融资余额22734.96亿元，融券余额161.62亿元。两市融资融券余额较前一交易日增加 356.81亿元。两市共有3442只个股有融资资金买入，其中新易盛、中际旭创、寒武纪排名前三，买入金 额分别45.48亿元、44.05亿元、41.05亿元。 华西证券表示，随着资本市场行情整体上行及交投热情升温，A股市场两融资金规模近期进一步增长， 并不断刷新阶段性纪录，反映出投资者对后市的乐观态度。 中国银河证券研报称，A股下一阶段大概率将延续震荡上行的走势。科技自立、内需消费及红利股方向 具备中长期配置价值。９月业绩为锚，10月政策为帆。展望下一阶段，短期预计市场在偏高中枢运行， 经历前期上涨行情后，市场或将阶段性呈现震荡整固特点。但当前市场成交维持活跃，资金面持续驱动 叠加政策预期升温，为市场行情提供支撑。 该机构认为，中长期聚焦三条主线，一是供需格 ...

招银国际发布研报称，映恩生物上半年收入12.3亿元人民币，同比增长23%，主要由授权与合作款项推 动。虽然公司目前尚未有商业化产品，但其与BioNTech、百济神州及葛兰素史克等企业建立的广泛合 作关系，潜在交易总价值超过60亿美元，加上未来可能扩展的合作项目，预计将在临床项目推进过程中 提供持续的资金支持。 消息面上，映恩生物公布中期业绩，上半年收入约12.29亿元，同比增长22.9%；经调整期内利润约1.46 亿元，同比增长14.2%。公告称，收入增加主要由于通过对外授权及合作协议进一步扩展研发活动。 映恩生物-B(09606)早盘涨超5%，截至发稿，涨3.67%，报362港元，成交额1.04亿港元。 ...